Operating margins doubled to 39.8% while the market prices only 1.43% growth — a pharmaceutical fortress hiding in plain sight.
This framework sees a widening moat pharmaceutical franchise trading at a discount while management pours record R&D into the future.
Does this business have a durable competitive advantage?
This framework sees a fortress. The margin expansion while increasing R&D 22% reveals not cost-cutting but structural competitive advantages. The diversified portfolio across 15+ products with demonstrated pricing power suggests a moat both wide and widening.
How much cash does an owner actually get to keep?
Applying this lens reveals exceptional cash generation. The company converts nearly all earnings to cash while investing heavily in R&D. The negative cash cycle means suppliers essentially finance operations — a mark of bargaining power.
Are the earnings predictable and consistent?
This framework values predictability above all else. A 94.9% beat rate over nearly 10 years demonstrates exactly the earnings consistency Buffett seeks. The ability to expand margins during crises shows resilience.
If you bought this entire business today, would the earnings justify the price?
The math reveals a paradox. Quality metrics are at decade highs while the market prices minimal growth. Trading at a 68.6% discount to DCF suggests the earnings more than justify the price for a patient owner willing to look past treasury comparisons.
Applying the Buffett framework reveals a pharmaceutical compounder with a widening moat, predictable earnings, and exceptional cash generation trading at a significant discount to intrinsic value. The 39.8% operating margins and 94.9% earnings beat rate demonstrate exactly the quality this framework seeks. While the 0.76% earnings yield appears unattractive against 4.3% treasuries, the 68.6% discount to DCF and management's aggressive R&D investment suggest the market underestimates the durability of this franchise. Would you rather own treasuries at 4.3% or a piece of a business generating $8.1B in free cash flow with demonstrated pricing power?
This analysis applies Warren Buffett's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Warren Buffett. Educational purposes only. Not financial advice.